This is Legit folks http://investorshangout.com/post/view?id=4400905
It is 2015 Business Report on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
done by: Dun & Bradstreet -WHO IS D & B you ask??
http://www.dbisrael.co.il/english/
Dun & Bradstreet, the leading Israeli and international company providing business information solutions for managing business risks and opportunities.
Dun & Bradstreet was founded in the United States of America in 1841, and today operates in 195 countries around the world. The company has the world’s largest database of commercial information, ][/color covering over 250 million businesses worldwide, and 1.5 million businesses in Israel.
Since its arrival to Israel in 1961, Dun & Bradstreet has supported the different sectors of the Israeli economy, accompanying businesses, managers, and decision makers and helping them to generate, cultivate and develop optimal business relationships – and to flourish!
The 2015 Business Report I found was a Business Report done by Dun & Bradstreet, it listed all TEVA's business activities for 2014/2015
and it was NOT "pumped" by OWCP - that mention of ONE WORLD was buried near bottom of the Business report ///
20/07/2015:
Further to the info that subject approached One World Cannabis in order to
start negotiations for the purchase of patnents, it should be noted that
companies engaged in the line and mainly traded on the NYSE, surge by tens of
hundreds of percentages with each announcement of progress or additional
achievement in the development of products on the basis of the plant. 2,500
patents are presently registered in the line and another 20 are waiting for
approval. In Israel 460 patents are registered and another 10,500 are waiting
for approval. The largest buyer of the patents in the line is Sanofi Avantis
which has already bought 39 patents in the cannabis line, followed by Paizer
with 25 patents.
20/07/2015:
One World Cannabis recenetly reported results of research carried out at the
Sheba academic-medical center in which it was found that 60% of the common
Melanoma cancer cells died within 24 hours after the team examined how they
are affected by the active ingredients of the plant (THC and CBD) in various
dosage. The company is in the initial stage of developing a drug based on
cannabis for the treatment of cancer, but following the results it already
started to develop the drug by prescirption and license (in Israel) for those
entitled to medical cannabis who suffer from common Melanoma. It appears
subject asked One World to start negotiations for the purchase of its patents.
So, EVERYTHING else listed in the TEVA Business report done by D & B is accurate except the part mention ONE WORLD CANNABIS on the TEVA Business report. lol
This is 100% Legit guys, Read the whole Business Report, it lists everything of important TEVA did 2014/15 - https://www.dnb.com.tw/Report/Sample/BIR_Israel.pdf
And, lastly to PROVE the TEVA Business Report is/was accurate, as a reference I add this, from the TEVA Business report 2015 this:
From the report;
06/01/2015:
Talks between Teva Pharmaceuticals and Intec Pharma for Teva to buy exclusive
rights to Intec Pharma s proprietary Accordion Pill Levodopa fell through and
Teva has withdrawn its intentions, probably due to the many years that will
pass until the pill will reaches the market. <- Remember is from the D & B TEVA report
** This News story appeared 1 day AFTER the Jan 7, 2015 Dated reference on TEVA Business report, (proven its accuracy )
Talks between Teva, Intec on Accordion Pill collapse
Talks between Teva Pharmaceuticals and Intec Pharma for Teva to buy exclusive rights to Intec Pharma’s proprietary Accordion Pill Levodopa fell through about three weeks ago, TheMarker has learned. The Accordion Pill is made of biodegradable polymeric films folded to an accordion shape inside a standard-size capsule. Reaching the stomach, the capsule dissolves; the Accordion Pill unfolds and over the next 12 hours releases the drug in a controlled manner. Proprietary Accordion Levodopa, which is due to start Phase II clinical trials now, is being developed to better treat Parkinson’s disease and could have been used to extend patent protection over a key Teva drug, Azilect, which had annual sales of $418 million over the last 12 months. It would have also given Teva an edge in developing other treatments for other central nervous system diseases, an area the company is now focusing on. Intec shares rose 7.2% to a close of 52 agorot (13 cents). (Yoram Gabison)
http://www.haaretz.com/israel-news/business/d...p/1.635699
Again, EVERYTHING in the TEVA Business Report was accurate - so this is 100% True!
20/07/2015:
Further to the info that subject (TEVA)approached One World Cannabis in order to
start negotiations for the purchase of patnents, it should be noted that
companies engaged in the line and mainly traded on the NYSE, surge by tens of
hundreds of percentages with each announcement of progress or additional
achievement in the development of products on the basis of the plant. 2,500
patents are presently registered in the line and another 20 are waiting for
approval. In Israel 460 patents are registered and another 10,500 are waiting
for approval. The largest buyer of the patents in the line is Sanofi Avantis
which has already bought 39 patents in the cannabis line, followed by Paizer
with 25 patents.
It is 2015 Business Report on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
done by: Dun & Bradstreet -WHO IS D & B you ask??
http://www.dbisrael.co.il/english/
Dun & Bradstreet, the leading Israeli and international company providing business information solutions for managing business risks and opportunities.
Dun & Bradstreet was founded in the United States of America in 1841, and today operates in 195 countries around the world. The company has the world’s largest database of commercial information, ][/color covering over 250 million businesses worldwide, and 1.5 million businesses in Israel.
Since its arrival to Israel in 1961, Dun & Bradstreet has supported the different sectors of the Israeli economy, accompanying businesses, managers, and decision makers and helping them to generate, cultivate and develop optimal business relationships – and to flourish!
The 2015 Business Report I found was a Business Report done by Dun & Bradstreet, it listed all TEVA's business activities for 2014/2015
and it was NOT "pumped" by OWCP - that mention of ONE WORLD was buried near bottom of the Business report ///
20/07/2015:
Further to the info that subject approached One World Cannabis in order to
start negotiations for the purchase of patnents, it should be noted that
companies engaged in the line and mainly traded on the NYSE, surge by tens of
hundreds of percentages with each announcement of progress or additional
achievement in the development of products on the basis of the plant. 2,500
patents are presently registered in the line and another 20 are waiting for
approval. In Israel 460 patents are registered and another 10,500 are waiting
for approval. The largest buyer of the patents in the line is Sanofi Avantis
which has already bought 39 patents in the cannabis line, followed by Paizer
with 25 patents.
20/07/2015:
One World Cannabis recenetly reported results of research carried out at the
Sheba academic-medical center in which it was found that 60% of the common
Melanoma cancer cells died within 24 hours after the team examined how they
are affected by the active ingredients of the plant (THC and CBD) in various
dosage. The company is in the initial stage of developing a drug based on
cannabis for the treatment of cancer, but following the results it already
started to develop the drug by prescirption and license (in Israel) for those
entitled to medical cannabis who suffer from common Melanoma. It appears
subject asked One World to start negotiations for the purchase of its patents.
So, EVERYTHING else listed in the TEVA Business report done by D & B is accurate except the part mention ONE WORLD CANNABIS on the TEVA Business report. lol
This is 100% Legit guys, Read the whole Business Report, it lists everything of important TEVA did 2014/15 - https://www.dnb.com.tw/Report/Sample/BIR_Israel.pdf
And, lastly to PROVE the TEVA Business Report is/was accurate, as a reference I add this, from the TEVA Business report 2015 this:
From the report;
06/01/2015:
Talks between Teva Pharmaceuticals and Intec Pharma for Teva to buy exclusive
rights to Intec Pharma s proprietary Accordion Pill Levodopa fell through and
Teva has withdrawn its intentions, probably due to the many years that will
pass until the pill will reaches the market. <- Remember is from the D & B TEVA report
** This News story appeared 1 day AFTER the Jan 7, 2015 Dated reference on TEVA Business report, (proven its accuracy )
Talks between Teva, Intec on Accordion Pill collapse
Talks between Teva Pharmaceuticals and Intec Pharma for Teva to buy exclusive rights to Intec Pharma’s proprietary Accordion Pill Levodopa fell through about three weeks ago, TheMarker has learned. The Accordion Pill is made of biodegradable polymeric films folded to an accordion shape inside a standard-size capsule. Reaching the stomach, the capsule dissolves; the Accordion Pill unfolds and over the next 12 hours releases the drug in a controlled manner. Proprietary Accordion Levodopa, which is due to start Phase II clinical trials now, is being developed to better treat Parkinson’s disease and could have been used to extend patent protection over a key Teva drug, Azilect, which had annual sales of $418 million over the last 12 months. It would have also given Teva an edge in developing other treatments for other central nervous system diseases, an area the company is now focusing on. Intec shares rose 7.2% to a close of 52 agorot (13 cents). (Yoram Gabison)
http://www.haaretz.com/israel-news/business/d...p/1.635699
Again, EVERYTHING in the TEVA Business Report was accurate - so this is 100% True!
20/07/2015:
Further to the info that subject (TEVA)approached One World Cannabis in order to
start negotiations for the purchase of patnents, it should be noted that
companies engaged in the line and mainly traded on the NYSE, surge by tens of
hundreds of percentages with each announcement of progress or additional
achievement in the development of products on the basis of the plant. 2,500
patents are presently registered in the line and another 20 are waiting for
approval. In Israel 460 patents are registered and another 10,500 are waiting
for approval. The largest buyer of the patents in the line is Sanofi Avantis
which has already bought 39 patents in the cannabis line, followed by Paizer
with 25 patents.
2
